SCHEMBL4579101

SCHEMBL4579101

CCOC(=O)c1ccc(Nc2nc(-c3cccnc3)cs2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.71
NPC1 O15118 8/20 0.71
MEN1 O00255 11/20 0.70
KMT2A Q03164 11/20 0.70
GAA P10253 3/20 0.65
PKM P14618 1/20 0.65
VCP P55072 1/20 0.65
CASP3 P42574 2/20 0.64
SENP8 Q96LD8 2/20 0.64
SENP7 Q9BQF6 2/20 0.64
SENP6 Q9GZR1 2/20 0.64
MAPT P10636 5/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
LMNA P02545 1/20 0.61
MAPK1 P28482 2/20 0.61
TDP1 Q9NUW8 2/20 0.61
TP53 P04637 1/20 0.61
KDM4E B2RXH2 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205908 0.90 RAB9A (0.66) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL207402 0.87 RAB9A (0.62) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL717068 0.85 ABL1 (0.61) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL206904 0.85 MEN1 (0.67) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL14155921 0.83 RAB9A (1.00) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL208199 0.83 RAB9A (0.82) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL206596 0.83 RAB9A (0.71) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL2706337 0.83 MEN1 (0.64) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL715923 0.83 ABL1 (0.67) MEN1KMT2AGAASMN1; SMN2TDP1
SCHEMBL206917 0.83 NPC1 (0.61) RAB9ANPC1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007720-B1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2013-12-25 EP disclosed
US-8598168-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2013-12-03 US disclosed
EP-2007720-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2008-12-31 EP disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
WO-2007118137-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2007-10-18 WO disclosed
WO-2007118137-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 RAB9A 2909/4885NPC1 1197/4885MEN1 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.